Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Tricida Inc (TCDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,775,428
  • Shares Outstanding, K 49,140
  • Annual Sales, $ 0 K
  • Annual Income, $ -102,810 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.87
  • Number of Estimates 2
  • High Estimate -0.85
  • Low Estimate -0.88
  • Prior Year -0.60
  • Growth Rate Est. (year over year) -45.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.47 +18.35%
on 04/22/19
37.63 -4.17%
on 05/16/19
+4.55 (+14.44%)
since 04/17/19
3-Month
21.28 +69.45%
on 02/21/19
40.83 -11.68%
on 03/29/19
+13.00 (+56.37%)
since 02/15/19

Most Recent Stories

More News
Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Tricida, Inc. (Nasdaq: TCDA) today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share,...

JPM : 110.77 (-0.49%)
TCDA : 36.06 (-0.19%)
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

ALPN : 5.95 (+7.40%)
OTIC : 2.81 (-0.71%)
MTEM : 7.47 (-3.36%)
TCDA : 36.06 (-0.19%)
ATNM : 0.31 (+15.97%)
Tricida Announces Pricing of Public Offering of Common Stock

Tricida,Inc. (Nasdaq: TCDA) today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds...

JPM : 110.77 (-0.49%)
TCDA : 36.06 (-0.19%)
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

KALV : 23.80 (-2.34%)
ACRX : 2.90 (+3.94%)
ALPN : 5.95 (+7.40%)
OTIC : 2.81 (-0.71%)
MTEM : 7.47 (-3.36%)
TCDA : 36.06 (-0.19%)
ATNM : 0.31 (+15.97%)
Tricida Announces Proposed Public Offering of Common Stock

Tricida,Inc. (Nasdaq: TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by...

JPM : 110.77 (-0.49%)
TCDA : 36.06 (-0.19%)
Will Tricida Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Tricida.

TCDA : 36.06 (-0.19%)
Tricida Announces $200 Million Debt Facility With Hercules Capital

Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate TRC101 (veverimer), a non-absorbed, orally-administered polymer...

HTGC : 13.34 (-0.22%)
TCDA : 36.06 (-0.19%)
Tricida Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 28, 2019 / Tricida Inc (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, 2019 at 8:00 AM Eastern Time....

TCDA : 36.06 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade TCDA with:

Business Summary

Tricida, Inc. is a late-stage pharmaceutical company. It focuses on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular diseases. The company's product candidate consists of TRC101, a non-absorbed, orally-administered polymer drug designed to treat...

See More

Key Turning Points

2nd Resistance Point 37.39
1st Resistance Point 36.73
Last Price 36.06
1st Support Level 35.57
2nd Support Level 35.07

See More

52-Week High 40.83
Last Price 36.06
Fibonacci 61.8% 32.65
Fibonacci 50% 30.13
Fibonacci 38.2% 27.60
52-Week Low 19.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar